ibrutinib

AbbVie's stock falls after lymphoma treatment trial data disappoints
AbbVie's stock falls after lymphoma treatment trial data disappoints
Marketwatch
AbbVie
ibrutinib
clinical trials
lymphoma
Flag link:
Pharmacyclics' Lymphoma Drug Receives FDA Approval
Pharmacyclics' Lymphoma Drug Receives FDA Approval
TheStreet.com
Pharmacyclics
FDA
Imbruvica
mantle cell lymphoma
ibrutinib
Flag link:
Cleveland Clinic picks top 3 blockbuster drug candidates in the late-stage pipeline
Cleveland Clinic picks top 3 blockbuster drug candidates in the late-stage pipeline
Fierce Biotech
Cleveland Clinic
JNJ
Pharmacyclics
Novartis
serelaxin
ibrutinib
sofosbuvir
Gilead
Flag link:
Pharmacyclics' Ibrutinib Could Crown Its Turnaround Story
Pharmacyclics' Ibrutinib Could Crown Its Turnaround Story
Investors.com
Pharmacyclics
ibrutinib
Flag link:
7 Disruptive Drugs for the Next Decade
7 Disruptive Drugs for the Next Decade
Motley Fool
Tecfidera
Biogen Idec
Bristol-Myers Squibb
Eliquis
Pfizer
Roche
Kadcyla
Immunogen
sofosbuvir
Gilead
ibrutinib
Pharmacyclics
Sarepta
eteplirsen
LX4211
Lexicon Pharmaceuticals
Flag link:
[video]Cramer: Biggest blockbuster drug in ages?
[video]Cramer: Biggest blockbuster drug in ages?
CNBC
Pharmacyclics
ibrutinib
Flag link:
Rough market day for Nektar, while Pharmacyclics and Regeneron soar
Rough market day for Nektar, while Pharmacyclics and Regeneron soar
Marketwatch
Nektar
Pharmacyclics
Regeneron
osteoarthritis
NKTR-181
ibrutinib
Flag link:
Is the Tide About to Turn in the Fight Against Chronic Lymphocytic Leukemia?
Is the Tide About to Turn in the Fight Against Chronic Lymphocytic Leukemia?
Motley Fool
chronic lymphocytic leukemia
Sanofi
Campath
GSK
Arzerra
Roche
Rituxan
ibrutinib
Pharmacyclics
obinutuzumab
JNJ
Genmab
Flag link:
These 2 Companies Are the Biggest Winners of the FDA's Breakthrough Designation
These 2 Companies Are the Biggest Winners of the FDA's Breakthrough Designation
Motley Fool
FDA
breakthrough therapies
ibrutinib
Pharmacyclics
JNJ
Novartis
LDK378
serelaxin
daratumumab
Genmab
Flag link:
FDA grants priority review to blood cancer treatment from Pharmacyclics
FDA grants priority review to blood cancer treatment from Pharmacyclics
Yahoo/AP
FDA
Pharmacyclics
Janssen
JNJ
ibrutinib
mantle cell lymphoma
chronic lymphocytic leukemia
Flag link:
What Does The FDA's Breakthrough Designation Mean For Investors?
What Does The FDA's Breakthrough Designation Mean For Investors?
Seeking Alpha
FDA
breakthrough therapies
AbbVie
Alexion
Ariad Pharmaceuticals
Biomarin
Bristol-Myers Squibb
SynaGeva BioPharma
GSK
JNJ
Merck
Novartis
Pharmacyclics
Pfizer
Vertex Pharmaceuticals
daratumumab
ibrutinib
Kalydeco
lambrolizumab
palbociclib
LDK378
SD-101
obinutuzumab
serelaxin
asfotase alfa
bimagrumab
drisapersen
sebelipase alfa
Flag link:
Johnson & Johnson's 3 Most Promising Drugs (video)
Johnson & Johnson's 3 Most Promising Drugs (video)
Motley Fool
Zytiga
Pharmacyclics
JNJ
Invokana
ibrutinib
Flag link:
This Small Company Is Winning the War Against Blood Cancer
This Small Company Is Winning the War Against Blood Cancer
Motley Fool
Pharmacyclics
mantle cell lymphoma
small lymphocytic lymphoma
chronic lymphocytic leukemia
ibrutinib
Flag link:
Expedited Drug Approval May Push Up Pharmacyclics' Value And Stock Price
Expedited Drug Approval May Push Up Pharmacyclics' Value And Stock Price
Seeking Alpha
Pharmacyclics
ibrutinib
JNJ
chronic lymphocytic leukemia
mantle cell lymphoma
Flag link:
Breakthrough Status May Spur J&J Drug to Market Early
Breakthrough Status May Spur J&J Drug to Market Early
Bloomberg
JNJ
breakthrough therapies
ibrutinib
Pharmacyclics
chronic lymphocytic leukemia
mantle cell lymphoma
Flag link:
A Developing "Breakthrough" In Biotechnology that You Should Monitor
A Developing "Breakthrough" In Biotechnology that You Should Monitor
Motley Fool
Pharmacyclics
ibrutinib
blood cancer
JNJ
AbbVie
Flag link:
Will This Be the Breakthrough of All Breakthrough Therapy Drugs?
Will This Be the Breakthrough of All Breakthrough Therapy Drugs?
Motley Fool
breakthrough therapies
ibrutinib
Pharmacyclics
JNJ
chronic lymphocytic leukemia
Flag link:
Pharmacyclics and Johnson & Johnson submit blood cancer drug ibrutinib to FDA for approval
Pharmacyclics and Johnson & Johnson submit blood cancer drug ibrutinib to FDA for approval
Yahoo/AP
JNJ
Pharmacyclics
ibrutinib
chronic lymphocytic leukemia
Flag link:
[video]3 Blood Cancer Drug Hopefuls in the Spotlight
[video]3 Blood Cancer Drug Hopefuls in the Spotlight
Motley Fool
Infinity Pharmaceuticals
JNJ
Pharmacyclics
Gilead
non-Hodgkin's lymphoma
ibrutinib
Idelalisib
IPI-145
Flag link:
Making The Call: Pharmacyclics FDA Drug Approval Before Year End
Making The Call: Pharmacyclics FDA Drug Approval Before Year End
TheStreet.com
FDA
Pharmacyclics
JNJ
ibrutinib
B-cell cancers
Flag link:

Pages